Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Colomer

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 23, 2008
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancerA Jimeno, C Grávalos, P Escudero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domainR Colomer, A Llombart-Cussac, A Lluch, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2006
Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, SpainJ Rubió, R Marcos-Gragera, M R Ortiz, et al.
Bone Marrow Transplantation|April 3, 2001
High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trialJ L Pérez-Gracia, R Colomer, A Ruiz-Casado, et al.
Journal of the National Cancer Institute|June 7, 1995
Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factorsJ I Mayordomo, F Rivera, M T Díaz-Puente, et al.
Cancer|December 18, 2001
High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trialJ L Pérez-Gracia, R Colomer, E Esteban, et al.
Gynecologic Oncology|August 6, 2008
Novel chemotherapy approaches in chemoradiation protocolsLucía González-Cortijo, N Carballo, A González-Martín, et al.
British Journal of Cancer|February 16, 2013
In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumoursM Quintela-Fandino, M Krzyzanowska, G Duncan, et al.
British Journal of Cancer|July 25, 2014
Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)M Quintela-Fandino, A Urruticoechea, J Guerra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety studyS M Swain, M S Ewer, G Viale, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 23, 2008
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancerA Jimeno, C Grávalos, P Escudero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domainR Colomer, A Llombart-Cussac, A Lluch, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2006
Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, SpainJ Rubió, R Marcos-Gragera, M R Ortiz, et al.
Bone Marrow Transplantation|April 3, 2001
High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trialJ L Pérez-Gracia, R Colomer, A Ruiz-Casado, et al.
Journal of the National Cancer Institute|June 7, 1995
Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factorsJ I Mayordomo, F Rivera, M T Díaz-Puente, et al.
Cancer|December 18, 2001
High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trialJ L Pérez-Gracia, R Colomer, E Esteban, et al.
Gynecologic Oncology|August 6, 2008
Novel chemotherapy approaches in chemoradiation protocolsLucía González-Cortijo, N Carballo, A González-Martín, et al.
British Journal of Cancer|February 16, 2013
In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumoursM Quintela-Fandino, M Krzyzanowska, G Duncan, et al.
British Journal of Cancer|July 25, 2014
Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)M Quintela-Fandino, A Urruticoechea, J Guerra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety studyS M Swain, M S Ewer, G Viale, et al.
Pageof 10